We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for deve... Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. Show more
β TIME recognizes Dr. Mendellβs decades-long contributions in the treatment of neuromuscular disease and the advancement of gene therapy, including the first gene therapy for Duchenne muscular...
Net product revenues for the first quarter 2024 totaled $359.5 million, a 55% increase over the same quarter of the prior year ELEVIDYS net revenues for the quarter totaled $133.9 million...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -5.525 | -4.13702733059 | 133.55 | 134.715 | 127.795 | 925834 | 132.10802489 | CS |
4 | 10.525 | 8.95744680851 | 117.5 | 146.68 | 117.06 | 1173337 | 130.66482308 | CS |
12 | -10.705 | -7.71642759317 | 138.73 | 146.68 | 114.37 | 908969 | 127.53186667 | CS |
26 | 42.995 | 50.5645066447 | 85.03 | 146.68 | 78.67 | 1054122 | 115.60662884 | CS |
52 | -22.325 | -14.8486863984 | 150.35 | 152.21 | 55.25 | 1200368 | 108.80084997 | CS |
156 | 47.715 | 59.4135225999 | 80.31 | 159.89 | 55.25 | 1103234 | 103.87394208 | CS |
260 | 9.905 | 8.38554012868 | 118.12 | 181.83 | 55.25 | 1134018 | 107.75712085 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions